STG-001 / Stargazer Pharma - LARVOL DELTA

Economic Burden and Changing Treatment Landscape in Stargardt Disease: A Literature and Database Review (ISPOR-EU 2023) - "Seven trials investigated 5 drug interventions (emixustat, tinlarebant, STG-001, avacincaptad pegol, ALK-001) with the eighth trial investigating a gene therapy (GT) (vMCO-010). The current healthcare costs associated with SD are not well established. With uncertainty around the current economic burden of SD, it will be difficult to determine the economic impact of new treatment options when making access decisions. Future analysis of analogues from other ocular degeneration disorders may prove useful in determining the current economic burden of SD."

HEOR • Review • Gene Therapies • Inherited Retinal Dystrophy • Ophthalmology • Retinal Disorders • ALK

Retinol binding protein 4 antagonists and protein synthesis inhibitors: Potential for therapeutic development. (PubMed, Eur J Med Chem) - "Two RBP4 antagonists, specifically tinlarebant (Belite Bio) and STG-001 (Stargazer) are currently undergoing clinical trials. Some antidiabetic drugs and nutraceuticals have been reported to reduce RBP4 expression, but more clinical data is needed to evaluate their therapeutical benefits. As regulating RBP4 levels or its activities would benefit a wide range of patients, further research is highly recommended to develop clinically useful RBP4 antagonists or protein synthesis inhibitors."

Journal • Review • Age-related Macular Degeneration • Cardiovascular • Diabetes • Genetic Disorders • Macular Degeneration • Metabolic Disorders • Obesity • Ophthalmology • Retinal Disorders • Type 2 Diabetes Mellitus

Study of STG-001 in Subjects With Stargardt Disease (clinicaltrials.gov) - P2a; N=10; Completed; Sponsor: Stargazer Pharmaceuticals, Inc.; Recruiting ➔ Completed

Clinical • Trial completion • Inherited Retinal Dystrophy • Ophthalmology • Retinal Disorders

Study of STG-001 in Subjects With Stargardt Disease (clinicaltrials.gov) - P2a; N=12; Recruiting; Sponsor: Stargazer Pharmaceuticals, Inc.; Trial primary completion date: Dec 2020 ➔ Mar 2021

Clinical • Trial primary completion date • Inherited Retinal Dystrophy • Ophthalmology • Retinal Disorders

Study of STG-001 in Subjects With Stargardt Disease (clinicaltrials.gov) - P2a; N=12; Recruiting; Sponsor: Stargazer Pharmaceuticals, Inc.; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Inherited Retinal Dystrophy • Ophthalmology • Retinal Disorders

Study of STG-001 in Subjects With Stargardt Disease (clinicaltrials.gov) - P2a; N=12; Not yet recruiting; Sponsor: Stargazer Pharmaceuticals, Inc.

Clinical • New P2a trial • Inherited Retinal Dystrophy • Ophthalmology • Retinal Disorders